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Volume 58, Number 6 Abstracts 1725Results: Based on the ﬁndings of the standardized preoperative ques-
tionnaire, patient centered outcomes for success were deﬁned as (1) main-
tenance of living independence, (2) maintenance of ambulatory status, (3)
control/relief of pain, (4) no additional/nonroutine physician visits, and
(5) survival for 1 year. While overall success for maintenance of indepen-
dence was 89% (n ¼ 849), maintenance of ambulation 84% (n ¼ 802),
control/relief of pain 48% (n ¼ 461), no additional physician visits 36%
(n ¼ 340), and 1-year survival 79% (n ¼ 755), overall patient centered
success (achievement of all ﬁve parameters) was accomplished in only
23% (n ¼ 218) of patients. Of 20 variables examined, only end-stage renal
disease (odds ratio [95% conﬁdence interval, 2.21 [1.26-3.88]; P ¼ .006)
and impaired ambulatory status preoperatively (odds ratio [95% conﬁdence
interval 1.76 [1.12-2.79]; P ¼ .015) were independent predictors of failure
using bivariate and multivariate analysis. Type of intervention (open vs
endo) was not a predictor of outcome. The probability of failing to achieve
patient centered success was 88% in patients with end-stage renal disease,
83% in patients with impaired ambulatory status preoperatively, and 93%
in patients with both (representing 30% of the entire patient cohort).
The probability of failure was still 73% even when neither predictor was
present.
Conclusions: When allowing patients to deﬁne successful outcome
after intervention for CLI, success was achieved in fewer than 25% of cases.
Patients with end-stage renal disease and impaired ambulatory status rarely
achieved success. These data reiterate that CLI is associated with declining
overall health undeterred by vascular intervention and question whether
intervention is an appropriate use of healthcare resources in various high
risk cohorts.
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Objectives: The risk of deterministic skin injury is determined by the
dose of ionizing radiation in any given procedure. Transient erythema
occurs at doses of 2-5 Gy, while permanent epilation, ulceration, and
desquamation are expected at doses above this level. Complex endovascular
procedures (CEP) such as fenestrated endovascular aortic stent grafts
(FEVAR) are associated with high radiation doses. Although CEP cases
are being performed with increasing frequency, the risk of associated skin
injury has not been examined. We hypothesized that skin injury following
these exposures is likely under recognized and under reported. This study
examined the frequency and severity of deterministic effects and evaluated
patient characteristics that might predispose to radiation injury in CEP
Methods: CEP was deﬁned as a procedure with a radiation dose $Gy
(NCRP threshold for substantial radiation dose level [SRDL]). Radiation
dose and operating factors were recorded for all CEP performed in a hybrid
room over a 30-month period. Patient medical records were retrospectively
reviewed for evidence of skin injury. Patients were seen in follow-up daily
until discharge and then at weeks 2, 6, months 3, 6, and 1 year. Phone inter-
views were conducted to determine the presence of any skin related
complaints, including erythema, epilation, and necrosis. Peak skin dose
(PSD) distributions were calculated for FEVARs using custom software
employing input data from ﬂuoroscopic machine logs. These calculations
were validated against gafchromic ﬁlm measurements. The effects of patient
factors and procedural skin dose on cutaneous skin injury were analyzed for
statistical signiﬁcance. Dose was summed for the subset of patients with
multiple procedures within 6 months of the SRDL event, consistent with
Joint Commission recommendations.
Results: 61 CEP reached a RAK of 5 Gy. There were 50 FEVARs, 6
embolizations, 1 TEVAR, 1 EVAR, 1 carotid, and 2 visceral interventions.
The patient cohort was 79% male and had a mean body mass index of 31.
The average RAK was 8 6 2 Gy (5.0-5.9 Gy). 16 patients had multiple
CEPs within 6 months of the SRDL event, with a mean cumulative RAK
of 12 6 3 Gy (7.0-18.4 Gy) for this patient subset. The mean FEVAR
PSD was 6.8 6 3.4 Gy (3.7-17.8 Gy), with a mean PSD/RAK ratio of
0.67 6 0.12. Three patients were lost to follow-up before their ﬁrst postop-
erative visit. Patients were seen at 2 weeks (95%), 6 weeks (88%), 3 months
(84%), 6 months (73%), and 1 year (79%) following the SRDL event. No
radiation skin injuries were found. Two patients had skin complaints unre-
lated to radiation, an HSV culture positive focal outbreak of shingles 2
weeks following the procedure and a diffuse desquamating, erythematous
drug reaction.
Conclusions: Radiation doses in this study exceeded published
thresholds for cutaneous injury; yet, no radiation skin injuries were
observed. This data suggests that other variables besides radiation dose
may play a role in deterministic injuries. Nonetheless, deterministic skininjuries may be less frequent than previously reported, and the risk is not
increased in complex endovascular procedures.
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Objectives: Fenestrated devices currently require a 3- to 4-week
manufacturing period prior to implantation; as such, there have been efforts
to develop “off-the-shelf” (OTS) devices to reduce the time before deﬁni-
tive treatment can be accomplished. Initial estimates predicted that
60%-70% of patients might be amenable to this approach. We examined
all patients treated for complex aortic problems at our institution during
the past 12 months to evaluate the suitability and early outcomes of the
OTS devices vs commercially available endovascular options.
Methods: Between July 2012 and July 2013, patients undergoing
aortic aneurysm repair were extracted from a prospectively managed aortic
database. Two OTS devices, the Cook p-branch and the Endologix Ventana
device, were available thru clinical trials during this time frame. The custom
Cook Zenith Fenestrated device (ZFEN) was also available and Food and
Drug Administration approved during the study period. Patient demo-
graphics and suitability for repair with an OTS device were determined
based on anatomic criteria.
Results: Out of 178 aortic aneurysms treated at our institution during
this time period, there were a total of 94 patients with thoracoabdominal
aortic aneurysm (II-IV) including pararenal (suprarenal and juxtarenal)
aneurysms. Only 22 (23%) patients met anatomic criteria for OTS devices
with 16 patients having these investigational devices implanted. The major
exclusion criterion for the p-Branch device was renal artery location (axial
and circumferential) while the limiting factor for the Ventana device was
infra-SMA neck length restrictions. Four of the patients who would have
ﬁt criteria for an OTS device choose to have an Food and Drug Administra-
tion approved (ZFEN) device implanted instead and two patients opted for
open repair as a result of follow-up requirements. An additional 17 patients
received custom designed (ZFEN) devices (n ¼ 21, 22%), whereas 57 (61%)
others did not meet criteria for any available endovascular device and were
repaired using alternative management strategies. The mean age and
maximal aortic diameter of the two cohorts (OTS: ZFEN) was 71.8: 72.0
years (P ¼NS) and 61.3: 58.0 mm (P ¼NS), respectively. Technical success
was 100%, with an overall 30-day mortality of 2.7% (n ¼ 1, ZFEN). Major
complications occurred in four patients (11%: OTS-1, ZFEN-3) and
included renal dissection-1, superior mesenteric artery dissection-1, peri-
nephric hematoma-1, and contrast-induced nephropathy-1.
Conclusions: Pararenal aneurysms comprise the minority of patients
presenting for repair to a complex aortic referral center. While OTS device
strategies will reduce the waiting times for patients with complex aortic
aneurysmal disease, a signiﬁcant number will still require custom made
devices or other repairs until additional device designs become available.
Early experience with OTS devices does not demonstrate any signiﬁcant
renal risks, however, the treatment numbers are low and should be inter-
preted with caution until larger conﬁrmatory studies are published. Further
studies comparing the outcomes of these techniques are required to estab-
lish the best approach to handle endovascular repair of complex aortic
aneurysms.
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Objectives: Cardiovascular disease is the leading cause of death in the
United States; nevertheless, there are no optimal or universally accepted
screening tests for disseminated atherosclerosis. Patients with peripheral
artery disease (PAD) are at increased risk for having atherosclerosis in addi-
tional vascular territories. The goal of this study was to determine the
utility of the ankle brachial index (ABI) value to predict coronary artery
disease (CAD), cerebrovascular disease (CVD), and carotid artery stenosis
(CAS).
Methods: A database of 3,561,679 subjects who underwent vascular
screening was used. PAD was deﬁned as an ABI # 0.9. CAS was diagnosed
if either artery demonstrated$50% stenosis. CVD and CAD history was ob-
tained from subject questionnaires. Correlation of decreasing ABI values
with vascular disease in other territories was performed.
Results: PAD was present in 125,889 subjects (3.5%). PAD subjects
were more likely to be >70 years (55.1% vs 25.9%), male (66.2% vs
62.2%), to have a smoking history (59.7% vs 43%), hypertension (62.1%
vs 43.9%), diabetes (20.2% vs 9.6%), and hypercholesterolemia (56.1% vs
